NASDAQ:JAZZ

Jazz Pharmaceuticals Earning Date

USA |NASDAQ |USD

JAZZ Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 1, 2021 Sep 2021 $3.31 $3.90 $4.31
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 1, 2021 Sep 2021 $832.52M $751.81M $600.89M

Jazz Pharmaceuticals's next earnings date is Monday, Nov 1, 2021 for the fiscal quarter ending Sep 2021.

JAZZ Earnings Date & History Chart

JAZZ Earnings & Revenue Forecast

JAZZ Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 18 $3.41 $2.71 $3.94
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 15 $14.52 $13.76 $15.29
Dec 2022 18 $17.44 $14.52 $20.16

JAZZ Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 2 / 0 $3.43 $3.43 $3.74
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 2 / 0 $14.50 $14.49 $14.55
Dec 2022 3 / 0 $17.66 $17.59 $17.90

JAZZ Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 16 $889.99M $864.00M $922.00M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 17 $3.09B $3.04B $3.16B
Dec 2022 18 $3.72B $3.50B $4.01B

JAZZ Earnings Date & Revenue History

JAZZ Earnings History

|
Show More
Show More

JAZZ Revenue History

|
Show More
Show More

Jazz Pharmaceuticals Next Earnings Date & Report

JAZZ Next Earnings Date & Report Preview: Sep 2021 (FQ)

JAZZ's next earnings date is Monday, Nov 1, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 18 analysts, the average EPS estimation for Jazz Pharmaceuticals's next quarterly earnings is $3.31, with a low EPS estimation of $2.99, and a high estimation of $3.69.

Over the last 1 month, EPS estimates have seen 5 upward revisions and 0 downward. The EPS 1 month trend is $3.26, the last 2 month trend is $3.26, and the 3 month trend is $3.36.

Based on 14 analysts, the average revenue estimation is $832.52M, with a low revenue estimation of $789.00M, and a high estimation of $860.50M.

Jazz Pharmaceuticals Previous Earnings Dates & Reports

JAZZ Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Jazz Pharmaceuticals's previous earnings date was Aug 3, 2021 for its fiscal quarter ended Jun 30, 2021.

JAZZ's earnings per share (EPS) was $3.90, beating the consensus analysts forecast of $3.45 by 13.15%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by -0.51%, and higher than the same period a year before (Jun 2020) by 5.12%.

Revenues were $751.81M, better than the forecast of $751.81M by 0.00%, up by 23.74% from the previous quarter , and up by 33.67% from the same period last year.

The company reported a net income of $-363.32M.

Free cash flow for the quarter was $34.52M , compared to $282.83M last quarter and $76.83M a year before.

JAZZ ended the quarter with $6.92B in total debt, an increase of 207.11% compared to the previous quarter, and an increase of 228.82% compared to the same quarter a year before.

JAZZ Previous Earnings Date & Report Recap: Dec 2020 (FY)

Jazz Pharmaceuticals's previous annual earnings date was Feb 23, 2021 for its fiscal year ended Dec 31, 2020.

JAZZ's earnings per share (EPS) was $12.47, missing the consensus analysts forecast of $12.60 by -1.03% , and lower than the previous year's EPS (Dec 2019) by -23.21%.

Revenues were $2.36B, better than the forecast of $2.34B by 1.08%, and up by 9.34% from previous year's revenue.

The company reported a net income of $238.62M, -54.41% lower than the previous year.

Jazz Pharmaceuticals reported a free cash flow of $520.39M for its fiscal year, compared to $594.07M a year ago.

The company ended the fiscal year with $2.11B in total debt, an increase of 30.20% compared to the previous year.